Key result
Percutaneous mitral valve dilatation is linked to ~4% systemic embolism risk from catheter-induced thrombi.
Why the study?
Systemic embolism is a potential and severe complication of percutaneous mitral valve dilatation with unclear causes and prevention strategies.
What is the incidence and mechanism of systemic embolism in patients undergoing percutaneous mitral valvuloplasty?
Observational (n=80)
What is the incidence and mechanism of systemic embolism in patients undergoing percutaneous mitral valvuloplasty?
Systemic embolism during percutaneous mitral valvuloplasty can occur due to catheter-induced thrombi from inadequate heparinization or calcific embolism, highlighting the need for full-dose heparin during the procedure.
Answers are grounded in this paper and cite their sources.
Embolism risk in mitral dilatation warrants vigilant heparinization; Level 5 data leaves optimal protocols open for prospective trials.
Systemic embolism is a potential and severe complication of percutaneous mitral valve dilatation. In our series of 80 cases, the incidence of systemic embolism was 3.75% (3 cases). Two cases occurred during the procedure itself. The cause of embolism was different in each case: cruoric thrombus formation occurred in 2 cases during or after dilatation, and was attributable to inappropriate heparinization, and catheter and guidewire thrombogenicity. In both cases heparin administration was delayed or given at a lower dosage. In the third case, calcific embolism occurred several days after valve dilatation. We think that the embolic calcified fragment was detached from the mitral leaflet at the time of or after balloon inflation. In these 3 cases, intraatrial thrombus mobilization was not the mechanism of systemic embolism. In 2 cases, transesophageal echocardiography had been performed before dilatation and excluded the presence of an atrial thrombus the day before the procedure. It is concluded that, together with mobilisation of left atrial thrombi, which can be adequately detected by transesophageal echocardiography, catheter-induced thrombi represent a significant cause of embolic complications and must be prevented by giving full-dose heparin during the total duration of the procedure. Calcific embolism may also occur, and may become more frequent if mitral valve balloon dilatation is proposed to a larger number of patients with valvular and subvalvular calcifications.
No takes yet. Share an insight, caveat, or question.
Drobinski et al. (1992) conducted an observational in Percutaneous mitral valvuloplasty (n=80). Percutaneous mitral valve dilatation was evaluated on Systemic embolism. Percutaneous mitral valve dilatation was associated with a 3.75% incidence of systemic embolism (3 of 80 cases), attributed to catheter-induced thrombi and calcific embolism.
Synapse has enriched 10 related papers. Consider them for comparative context: